
uniQure Investor Relations Material
Latest events

Study Update
uniQure
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from uniQure N.V.
Access all reports
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Through its adeno-associated virus (AAV) based gene therapy platform, the company develops proprietary power gene therapies that can be used to treat diseases with a high unmet need. Its lead program is focused on Hemophilia B and Huntington's disease.
Key slides for uniQure N.V.


Study Update
uniQure N.V.


Study Update
uniQure N.V.
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
QURE
Country
🇺🇸 United States